BRAF and malignant colon neoplasm: The PETACC-3 study [13], which analyzed BRAF and KRAS mutations in 1,404 colon cancer patients, demonstrating that patients with the BRAF mutation had inferior OS compared to those with the wild type, and the contrast was more pronounced when stratified by microsatellite instability (MSI).